Completed

Phase 3
Age: 18Years +
All Genders
ID01691846

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Plus Metformin Combination Therapy Compared With Placebo Plus Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

Led by Hoffmann-La Roche · Updated on 2017-02-23

200

Participants Needed

31

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar plus metformin combination therapy compared with placebo plus metformin in patients with type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.

CONDITIONS

Brief Title

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients, >/=18 years of age
  • Diagnosis of diabetes mellitus type 2
  • Patients treated with stable metformin monotherapy for at least 12 weeks prior to screening
  • HbA1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
  • Fasting plasma glucose </=240 mg/dL at pre-randomization visit
  • Agreement to maintain diet and exercise habits during the study
Not Eligible

You will not qualify if you...

  • Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
  • Any previous treatment with thiazolidinedione or a dual PPAR agonist
  • Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
  • Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening

Trial Site Locations

Total: 31 locations

1

Chino, California, United States, 91710

Status Unknown

2

Hawaiian Gardens, California, United States, 90716

Status Unknown

3

Los Angeles, California, United States, 90057

Status Unknown

4

Santa Ana, California, United States, 92701

Status Unknown

5

Thousand Oaks, California, United States, 91360

Status Unknown

6

West Hills, California, United States, 91307

Status Unknown

7

Kissimmee, Florida, United States, 34741

Status Unknown

8

Atlanta, Georgia, United States, 30338

Status Unknown

9

Chicago, Illinois, United States, 60607

Status Unknown

10

Avon, Indiana, United States, 46123

Status Unknown

11

Bethesda, Maryland, United States, 20817

Status Unknown

12

Springfield, Missouri, United States, 65807

Status Unknown

13

Toms River, New Jersey, United States, 08753

Status Unknown

14

Altoona, Pennsylvania, United States, 16602

Status Unknown

15

Beaver, Pennsylvania, United States, 15009

Status Unknown

16

Morrisville, Pennsylvania, United States, 19067

Status Unknown

17

Scranton, Pennsylvania, United States, 18510

Status Unknown

18

Tipton, Pennsylvania, United States, 16684

Status Unknown

19

Knoxville, Tennessee, United States, 37919

Status Unknown

20

Dallas, Texas, United States, 75230

Status Unknown

21

Richmond, Virginia, United States, 23249

Status Unknown

22

Spokane, Washington, United States, 99202

Status Unknown

23

Buenos Aires, Argentina, 1056

Status Unknown

24

Caba, Argentina, C1428DCO

Status Unknown

25

Rosario, Argentina, S2000CXP

Status Unknown

26

Cuernavaca, Mexico, 62250

Status Unknown

27

Culiacán, Mexico, 80020

Status Unknown

28

Guadalajara, Mexico, 44650

Status Unknown

29

Mexico City, Mexico, 11650

Status Unknown

30

Pachuca, Mexico, 42060

Status Unknown

31

Tampico, Mexico, 89000

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Improved Adipose Tissue Storage of Dietary Fatty Acids as a ...

Diabetes Mellitus Type 2

Actively Recruiting

1 location

AI-Based Phenome Data Analysis for Predicting the Onset of M...

Diabetes Mellitus Type 2

Actively Recruiting

1 location

EMPOWERing Patients With Chronic Diseases Through Smartphone...

Diabetes Mellitus Type 2

Actively Recruiting

2 locations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here